Working… Menu

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03236428
Recruitment Status : Active, not recruiting
First Posted : August 1, 2017
Last Update Posted : February 2, 2021
Janssen Pharmaceuticals
Multiple Myeloma Research Consortium
Blood Cancer Research Partnership
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Irene Ghobrial, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2023